Welcome
Driving Global Pharma Products from Lab to Market.
I specialize in turning Pharma R & D into scalable, compliant, and profitable outcomes- from molecules to market.
My work has consistency delivered 50% growth, 30% efficiency gains, and zero compliance failure, while accelerating product launches and empowering global teams.
 |  |  |
|---|---|---|
 |  |  |
Vertex Pharmaceuticals — Strategic Innovation & Portfolio Analysis
I translated a complex pharmaceutical growth challenge into three priorities, four technology perspectives, and one time bound execution agenda—demonstrating how scientific innovation can be connected to operational readiness and enterprise value.
Power in Numbers
$12B (Evaluated the portfolio, pipeline, and execution system supporting Vertex’s $12 billion 2025 revenue base).
Programs
93% (Approximately 93% of 2025 revenue came from TRIKAFTA/KAFTRIO and ALYFTREK, demonstrating why portfolio diversification is strategically important).
Locations
$500M+ (Assessed the strategic significance of Vertex’s expectation for non-CF products to contribute at least $500 million in 2026).
Volunteers